Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)

v3.23.3
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 29, 2022
shares
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2023
USD ($)
segment
shares
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
shares
Oct. 27, 2022
shares
Oct. 26, 2022
shares
Number of Operating Segments | segment       2          
Proceeds from Divestiture of Interest in Consolidated Subsidiaries           $ 17,824      
Revenue from Contract with Customer, Excluding Assessed Tax       $ 276,935   269,655      
Gain on sale of Eminence       0   11,682      
Gain (loss) on equity method investment       $ (2,290)          
Common stock, shares authorized (in shares) | shares       400,000,000     400,000,000 400,000,000 100,000,000
Declared stock split 4                
Additional shares | shares 3                
Eminence Biotechnology                  
Proceeds from Divestiture of Interest in Consolidated Subsidiaries   $ 17,800              
Protein Sciences                  
Pre-tax restructuring charges             $ 1,700    
Protein Sciences | Eminence Biotechnology                  
Revenue from Contract with Customer, Excluding Assessed Tax           2,000      
Wilson Wolf Corporation                  
Investment percentage         19.90%        
Gain (loss) on equity method investment       $ (2,300)          
Investment amount       $ 252,000          
Payments to Acquire Investments, Total     $ 25,000   $ 232,000        
Forward Contract, Milestone, Multiple for Total Expected Payments       4.4          
Wilson Wolf Corporation | First Part of Forward Contract                  
Forward Contract, Milestone, Annual Revenue Required       $ 92,000          
Forward Contract, Milestone, Annual EBITDA       55,000          
Wilson Wolf Corporation | Second Part of Forward Contract                  
Forward Contract, Milestone, Annual Revenue Required       226,000          
Forward Contract, Milestone, Annual EBITDA       136,000          
Forward Contract, Additional Investment       $ 1,000,000          
QT Holdings Corporation | Protein Sciences                  
Pre-tax restructuring charges             $ 2,200    
Eminence Biotechnology                  
Gain on sale of Eminence           11,700      
Eminence Biotechnology | Nonoperating Income (Expense)                  
Gain on sale of Eminence           $ 11,700